Patent · US Active

Compositions comprising cross-species-specific antibodies and uses thereof

US11925684B2 · kind B2 · utility

0Cited by

4References

16Claims

0Family size

Assignee

AMGEN RESEARCH (MUNICH) GMBH · DE

Inventors

Roman Kischel · Munich, DE
Tobias Raum · Munich, DE
Bernd Schlereth · Germering, DE
Doris Rau · Munich, DE
Ronny Cierpka · Munich, DE
Peter Kufer · Munich, DE

Key dates

Filing date	Aug 29, 2018
Grant date	Mar 12, 2024
Priority date	—
Expiry date	May 24, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/622
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to uses of bispecific antibodies exhibiting cross-species specificity for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of the same in non-human species and humans. The present invention moreover relates to methods for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of said bispecific antibodies exhibiting cross-species specificity. The present invention also relates to methods of measuring the biological activity and/or efficacy of such bispecific antibodies exhibiting cross-species specificity. In addition, the present invention relates to pharmaceutical compositions comprising bispecific single chain antibodies exhibiting cross-species specificity and to methods for the preparation of pharmaceutical compositions comprising said bispecific single chain antibodies exhibiting cross-species specificity for the treatment of diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.